ADAURA is the first phase III trial for Tagrisso to show statistically significant benefit in adjuvant treatment of EGFRm NSCLC.- AstraZeneca
Related news and insights
Blueprint Medicines Corporation announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG 451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced Conditional Marketing Authorisation (CMA) of Rybrevant (amivantamab) for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.
Spectrum Pharmaceuticals announced that it has submitted its New Drug Application (NDA) for poziotinib to the FDA for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations.